• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025.

    "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to ship, we believe 2026 will be a foundational year for scaling the beverage division and expanding our national footprint. In fact, through the first quarter of 2026, we've already generated over $600,000 in gross revenue, nearly matching our full year 2025 performance. This equates to an annualized run rate of approximately $2.5 million, reflecting the meaningful progress we've made in expanding our functional beverage distribution."

    "In addition, due to instability in the Middle East, we agreed to cancel a licensing agreement with our regional partner. However, we continue to view this as an attractive long-term growth opportunity and intend to revisit this once conditions in the region stabilize. With a more focused portfolio, expanding retail and DSD partnerships, and growing consumer momentum, we believe Synergy is well positioned to drive sustainable growth in the quarters ahead."

    Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Period

    • Revenue of $6.07 million vs. $10.27 million.
    • Gross margin of 36.6% vs. 63.3%.
    • Income (loss) from operations of ($13.31) million vs. $1.35 million.
    • Net income (loss) of ($14.82) million vs. $105.7 thousand.
    • Earnings (loss) per share of ($1.35) vs. $0.01.
    • EBITDA (loss), a non-GAAP financial measure, was ($13.28) million vs. $1.68 million.
    • Adjusted EBITDA (loss), a non-GAAP financial measure, was $(4.48) million vs. $2.79 million.

    2025 Financial Summary vs. Same Year-Ago Period

    • Revenue of $30.38 million vs. $34.83 million.
    • Gross margin of 66.8% vs. 67.9%.
    • Income (loss) from operations of ($8.46) million vs. $5.80 million.
    • Net income (loss) of ($12.34) million vs. $2.12 million.
    • Earnings (loss) per share of ($1.27) vs. $0.28.
    • EBITDA (loss), a non-GAAP financial measure, was ($6.19) million vs. $6.46 million.
    • Adjusted EBITDA, a non-GAAP financial measure, was $800 thousand vs. $7.35 million.

    Fourth Quarter and Full Year 2025 Financial Results

    Revenue in the fourth quarter of 2025 was $6.07 million compared to $10.27 million in the fourth quarter of 2024, due to the termination of the license of $2.9 million. For the full year 2025, revenue was $30.38 million compared to $34.83 million in 2024, due to the termination of license agreement of $2.9 million.

    Gross margin in the fourth quarter of 2025 was 36.6% compared to 63.3% in the fourth quarter of 2024 due to the termination of license agreement of $2.9 million and a write off of obsolete inventory of $1.04 million. Without those two items, gross margin would have been 68.8%. For the full year 2025, gross margin was 66.8% compared to 67.9% in 2024.

    Operating expenses in the fourth quarter of 2025 were $15.53 million compared to $5.14 million in the fourth quarter of 2024. This is largely due to one-time items of an allowance for bad debt of $6.66 million and the write off of prepaid media credits of $0.9 million. Without those two items, operating expenses would have been $8.00 million. For the full year 2025, operating expenses were $28.76 million compared to $17.84 million in 2024, which is also due to the above-mentioned one-time items. Without those two items, operating expenses would have been $21.24 million.

    Income (loss) from operations for the fourth quarter of 2025 was ($13.31) million compared to $1.35 million in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, loss from operations would have been $(1.85) million. For the full year 2025, income (loss) from operations was ($8.46) million compared to $5.80 million in 2024, which is also due to the items listed above. Without those one-time items, the full year income from operations would have been $3.0 million.

    Net income (loss) in the fourth quarter of 2025 was ($14.82) million compared to net income of $105.7 thousand in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, net loss would have been $(3.35) million. For the full year 2025, net income (loss) was ($12.34) million compared to $2.12 million in 2024, which is also due to the items listed above offset by a gain on the settlement of notes payable of $2.15 million. Without those one-time items, the full year net loss would have been $(3.03) million.

    Earnings (loss) per share in the fourth quarter of 2025 was ($1.35) compared to $0.01 in the fourth quarter of 2024. For the full year 2025, earnings (loss) per share was ($1.27) compared to $0.28 in 2024.

    EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was ($13.28) million compared to $1.68 million in the fourth quarter of 2024. For the full year 2025, EBITDA (loss) was ($6.19) million compared to $6.46 million in 2024.

    Adjusted EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was $(4.48) million compared to $2.79 million in the fourth quarter of 2024. For the full year 2025, Adjusted EBITDA was $800 thousand compared to $7.35 million in 2024.

    Balance Sheet and Cash Flow

    As of December 31, 2025, Synergy had approximately $2.6 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

    As of December 31, 2025, Synergy had a working capital surplus of $1.78 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

    As of December 31, 2025, Synergy had $3.7 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

    Cash used in operating activities for the twelve months ended December 31, 2025 was $2.6 million compared to cash used in operating activities of $4.8 million for the twelve months ended December 31, 2024.

    Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA

    To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

    Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company's core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company's calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.

    The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):

      
     3 Months ended December 31
     20252024
       
    Net income for the period$(14.81)$0.10
    Adjusted for:  
    Interest expense, net1.551.54
    Amortization of intangible assets0.030.03
    Tax expense (benefit)(0.05)0.01
    EBITDA$(13.28)$1.68
    One-time expenses0.860.99
    Allowance for bad debts6.660.00
    Obsolete inventory1.040.13
    Foreign currency adjustment(0.13)0.00
    Stock based compensation0.37-
    Adjusted EBITDA$(4.48)$2.79



      
     12 Months ended December 31
     20252024
       
    Net income (loss) for the period$(12.34)$2.12
    Adjusted for:  
    Interest expense, net5.904.11
    Amortization of intangible assets0.130.13
    Tax expense0.120.10
    EBITDA$(6.19)$6.46
    One-time expenses0.860.74
    Allowance for bad debts6.660.00
    Gain on settlement of loan(2.15)0.00
    Obsolete inventory1.040.13
    Foreign currency adjustment0.020.03
    Stock based and board compensation0.560.00
    Adjusted EBITDA$0.80$7.35
       

    Conference Call

    In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on April 1, 2026, with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company's website.

    About Synergy CHC Corp.

    Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.

    Forward Looking Statements

    Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

    Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy's filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

    Investor Relations



    Gateway Group

    Cody Slach, Greg Robles

    949.574.3860

    [email protected] 

    Synergy CHC Corp.

    Condensed Consolidated Balance Sheets
           
      December 31,

    2025
      December 31,

    2024
     
    Assets      
    Current Assets      
    Cash and cash equivalents $2,622,313  $687,920 
    Restricted cash  100,000   100,000 
    Accounts receivable, net  3,203,505   5,321,037 
    Other receivables, net  -   1,999,637 
    Loan receivable (related party), net  -   4,375,059 
    Prepaid expenses (including related party amount of $110,803 and $312,966, respectively)  351,049   1,859,563 
    Inventory, net  3,737,509   1,716,552 
    Total Current Assets  10,014,376   16,059,768 
             
    Intangible assets, net  150,000   283,333 
             
    Total Assets $10,164,376  $16,343,101 
             
    Liabilities and Stockholders' Deficit        
    Current Liabilities:        
    Accounts payable and accrued liabilities (including payable to shareholder of $196,934 and $88,644, respectively) $6,388,219  $5,191,868 
    Income taxes payable  88,108   242,977 
    Contract liabilities  1,526   24,252 
    Short term loans payable, net of debt discount, related party  100,000   - 
    Short term loans payable, net of debt discount  -   7,725,272 
    Current portion of notes payable, net of debt discount  1,658,215   - 
    Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder  -   4,000,000 
    Total Current Liabilities  8,236,068   17,184,369 
             
    Long-term Liabilities:        
    Notes payable, net of debt discount, shareholder  -   8,333,053 
    Notes payable, net of debt discount  25,056,446   7,457,022 
    Total long-term liabilities  25,056,446   15,790,075 
    Total Liabilities  33,292,514   32,974,444 
             
    Commitments and contingencies (Note 13)        
             
    Stockholders' Deficit:        
    Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 and 8,721,818, shares issued, respectively; 11,303,853 and 8,541,745 outstanding, respectively  114   87 
    Additional paid in capital  33,594,550   27,643,660 
    Accumulated other comprehensive loss  (154,281)  (47,777)
    Accumulated deficit  (56,441,021)  (44,099,813)
    Less: Treasury stock (180,073 shares) at cost  (127,500)  (127,500)
    Total stockholders' deficit  (23,128,138)  (16,631,343)
    Total Liabilities and Stockholders' Deficit $10,164,376  $16,343,101 
             



    Synergy CHC Corp.

    Consolidated Statements of Operations and Other Comprehensive (Loss) Income
           
      For the

    year ended
      For the

    year ended
     
      December 31,

    2025
      December 31,

    2024
     
    Revenue $30,380,809  $34,834,243 
             
    Cost of sales  10,077,992   11,191,224 
             
    Gross Profit  20,302,817   23,643,019 
             
    Operating expenses        
    Selling and marketing  13,137,779   12,991,431 
    General and administrative  8,829,803   4,717,006 
    Reserve for bad debts  6,660,650   - 
    Depreciation and amortization  133,334   133,334 
    Total operating expenses  28,761,566   17,841,771 
             
    (Loss) Income from operations  (8,458,749)  5,801,248 
             
    Other (income) expenses        
    Other income  -   (510,534)
    Interest income  (15,065)  (1,523)
    Interest expense  5,919,742   4,105,198 
    Gain on settlement of notes payable  (2,154,522)  - 
    Remeasurement loss (gain) on translation of foreign subsidiary  14,833   (18,954)
             
    Total other expenses  3,764,988   3,574,187 
             
    Net (loss) income before income taxes  (12,223,737)  2,227,061 
    Income tax expense  117,471   102,085 
             
    Net (loss) income after tax $(12,341,208) $2,124,976 
             
    Net (loss) income per share – basic $(1.27) $0.28 
    Net (loss) income per share - diluted $(1.27) $0.28 
             
    Weighted average common shares outstanding        
    Basic  9,722,552   7,588,095 
    Diluted  9,722,552   7,630,501 
    Comprehensive (loss) income:        
    Net (loss) income $(12,341,208) $2,124,976 
    Foreign currency translation adjustment  (106,504)  54,690 
    Comprehensive (loss) income $(12,447,712) $2,179,666 
             



    Synergy CHC Corp.

    Consolidated Statements of Cash Flows
           
      For the

    year ended
      For the

    year ended
     
      December 31,

    2025
      December 31,

    2024
     
    Cash Flows from Operating Activities      
    Net (loss) income $(12,341,208) $2,124,976 
    Adjustments to reconcile net (loss) income to net cash used in operating activities:        
    Amortization of debt discount and debt issuance cost  1,633,776   56,796 
    Depreciation and amortization  133,334   133,334 
    Stock based compensation  136,247   - 
    Stock issued for modification of notes payable  847,062   - 
    Stock issued for services  127,200   - 
    Foreign currency transaction (gain) loss  5,531   54,321 
    Remeasurement gain on translation of foreign subsidiary  14,833   (18,954)
    Non cash implied interest  -   4,799 
    Bad debts  2,256,846   - 
    Bad debt, related party  4,403,804   - 
    Gain on settlement of debt  (2,154,522)  - 
    Write-off of inventory  894,341   125,364 
    Stock issued for loan financing  -   97,920 
    Income from employee retention credits  -   (252,405)
    Income from insurance on stolen goods  -   (258,129)
    Changes in operating assets and liabilities:        
    Accounts receivable  1,514,935   (3,214,943)
    Other receivables  345,388   (1,489,103)
    Loan receivable, related party  -   84,937 
    Inventory  (2,915,298)  1,884,324 
    Prepaid expenses  1,306,351   (1,250,023)
    Prepaid expense, related party  202,163   (145,092)
    Income taxes payable  (84,271)  57,312 
    Contract liabilities  (22,726)  10,050 
    Accounts payable and accrued liabilities  622,099   (2,870,633)
    Accounts payable, related party  489,093   61,759 
    Net cash used in operating activities  (2,585,022)  (4,803,390)
             
    Cash Flows from Investing Activities  -   - 
             
    Cash Flows from Financing Activities        
    Proceeds from issuance of common stock at IPO  -   8,397,044 
    Proceeds from issuing common stock  3,719,547   - 
    Advances from related party  235,000   3,528,003 
    Repayments of advances to related party  (135,000)  (3,200,000)
    Repayment of notes payable, shareholder  (10,000,000)  (84,500)
    Proceeds from notes payable  20,996,250   1,360,000 
    Payment of loan financing fees  (2,024,287)  - 
    Repayment of notes payable  (8,136,846)  (5,196,461)
    Net cash provided by financing activities  4,654,664   4,804,086 
             
    Effect of exchange rate on cash, cash equivalents and restricted cash  (135,249)  54,690 
    Net increase in cash, cash equivalents and restricted cash  1,934,393   55,386 
    Cash, Cash Equivalents and restricted cash, beginning of year  787,920   732,534 
    Cash, Cash Equivalents and restricted cash, end of year $2,722,313  $787,920 
             
    Supplemental Disclosure of Cash Flow Information:        
    Cash paid during the period for:        
    Interest $2,953,878  $3,906,001 
    Income taxes $147,377  $- 
             
    Supplemental Disclosure of Non-cash Investing and Financing Activities:        
    Accounts payable converted to loan payable upon settlement $-  $3,770,824 
    Reduction of short-term related party note payable by reduction of prepaid balance $-  $328,003 
    Issuance of common stock for loan financing $220,869  $- 
    Issuance of pre-funded warrants for settlement of shareholder notes payable $899,993  $- 
    Exercise of pre-funded warrants $4  $- 
    Loan fees payable to lender $375,000  $- 





    Primary Logo

    Get the next $SNYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    2/2/2026$5.00Buy
    Ascendiant Capital Markets
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thompson Teresa Brigid

    3 - Synergy CHC Corp. (0001562733) (Issuer)

    10/2/25 9:47:13 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by President Baumeler Alfred

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:31:24 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fickett Jaime

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:26:09 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    SEC Form 10-K filed by Synergy CHC Corp.

    10-K - Synergy CHC Corp. (0001562733) (Filer)

    3/31/26 9:23:47 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form NT 10-K filed by Synergy CHC Corp.

    NT 10-K - Synergy CHC Corp. (0001562733) (Filer)

    3/31/26 8:39:27 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Synergy CHC Corp. (0001562733) (Filer)

    3/25/26 4:15:20 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Synergy CHC Corp. with a new price target

    Ascendiant Capital Markets initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $5.00

    2/2/26 6:52:55 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of Directors

    Board member Scott Woodburn transitions to Head of Strategic Partnerships to accelerate FOCUSfactor Energy Drink expansion Former Costco Buyer Teresa Thompson brings nearly 40 years of retail expertise in vitamins and supplements WESTBROOK, Maine, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company's expansion in functional beverages, and Teresa Thompson has been appointed to Synergy's Board of Directors (the "Board"), effective immediately. In connection with Woodb

    9/22/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care